Bone-Modifying Agents in Patients With High-Risk Metastatic Castration-Sensitive Prostate Cancer Treated With Abiraterone Acetate.

ABSTRACT:

Importance

The association between the use of bone-modifying agents (BMAs) and the outcomes among patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with abiraterone acetate plus prednisone (AAP) remains unclear.

Objective

To investigate the association between BMA use and the outcomes of patients with mCSPC receiving AAP.

Design, setting, and participants

In this cohort study, a post hoc analysis of individual participant data from the LATITUDE trial was performed. The LATITUDE trial, a phase 3 randomized clinical trial, aimed to assess the efficacy of AAP and androgen deprivation therapy (ADT) vs dual-placebo and ADT in patients with high-risk mCSPC (data cutoff, August 15, 2018). Eligible patients had newly diagnosed prostate cancer with

SUBMITTER: Fukuokaya W 

PROVIDER: S-EPMC10943414 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature